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Abstract
Background: Mammogram screening for surveillance and detection of breast cancer has long
been recognized as a preventative health measure in primary care for women. However, easily
recognizing when to screen individual women, based on age and risk factors, lacks clear
guidance and often ends in fragmented and inconsistent practices among providers.
Methods: By developing and implementing the Screening Mammogram Initiation Protocol
(SMIP), the desired goals of this project were to: a) align breast cancer screening
recommendations to better meet individualized patient needs in primary care utilizing best
practice guidelines, b) increase the rate of breast cancer screening across various demographics,
and c) create a standardized screening protocol tool that increases shared decision making based
on individual risk factors. Outcome measures were reflected by an increase in provider
knowledge towards female breast health counseling, an increase in rates of breast cancer
screening discussions, and the successful implementation of the SMIP at a local primary care
clinic in Oakland, California.
Results: Responses from the pre/post knowledge and post-implementation surveys showed
improved provider understanding of the current breast cancer screening guidelines for average
and high-risk females as well as 90% satisfaction utilizing the SMIP in practice. Electronic data
collection after nine-weeks showed an eight percent increase (64% to 72%) in referrals for
women aged 40-49 eligible for breast cancer screening and seven percent increase (73% to 80%)
in referrals for women aged 50-59 eligible for breast cancer screening.
Conclusion: This evidence-based change in practice project ultimately improved the quality of
care by enhancing preventative health delivery, contribute to increased screening, and likely
impact breast cancer morbidity, and mortality rates.
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Section II: Introduction
Problem Description
In the United States, breast cancer continues to be the second most common cancer
diagnosis in females, and the second leading cause of cancer death in women (ACS, 2019;
Centers for Disease Control and Prevention [CDC], 2018). It is estimated, that in 2019, 268,600
new diagnoses of breast cancer will occur, and 10% of those new cases will be found in women
under the age of 45 (ACS, 2019; CDC, 2018; Surveillance, Epidemiology, and End Results
Program [SEER], n.d.). Of women under 45, breast cancer is most commonly found in the
African American race who also experience the overall highest death rate associated with breast
cancer in comparison to White, Asian, Pacific Islander, Native American, Hispanic, and NonHispanic women (Breastcancer.org, 2019; SEER, n.d.). Women with a first-degree relative
(mother, sister, daughter) with history of breast cancer have a near two-fold increased risk of
developing breast cancer (Breastcancer.org, 2019). The lifetime breast cancer risk for women
who have a BRCA1 or BRCA2 gene mutation is 72% and 69%, respectively and is more
prevalent in the younger population (Breastcancer.org, 2019). One in eight women will develop
breast cancer in their lifetime, 15% will have an associated first-degree relative, and 5-10% will
be related to a genetic mutation (ACS, 2019; Breastcancer.org, 2019).
Overview of the Current Guidelines
The recommendations for initiating breast cancer screening (BCS) with a mammogram,
the frequency with which to continue monitoring, and the screening discontinuation age differ
among reputable organizations and professional societies (Table 1).
Table 1:
Breast Cancer Screening Guidelines

7

STANDARDIZING MAMMOGRAM SCREENING

8

Group

Age to Initiate
Mammograms

Frequency (years)

Age to
Discontinue
Mammograms

Shared Decision
Making Approach

ACOG1

40*
No later than 50

1-2*

75, anything
beyond is
provider-patient
discussion

*Recommendation for
initiating the BCS
screening process to start
at age 40. The age to
begin mammography
requires an informed
decision based on
provider-patient
discussion about the
potential risks, benefits,
and patient
values/preferences.

ACR2

40

1

Life expectancy
<5-7 years or if no
further
intervention
planned regardless
of imaging results

Screening considerations
should include educating
women of the risks,
benefits, and limitations
of screening to help the
patient make an informed
decision.

ACS3

40-44
(Qualified
Recommendation)

1: ages 40-44 if
starting (Qualified
Recommendation)

Life expectancy
<10 years
(Qualified
Recommendation)

45
(Strong
Recommendation)

1: ages 45-54
(Qualified
Recommendation)

A qualified
recommendation is
interpreted as the health
care professional will
provide education on the
different options and help
the patient consider their
values/preferences to make
an informed decision.

Limited life
expectancy and no
further
intervention
planned regardless
of imaging results

Recommendations for
screening also
encourages counseling
women on the potential
risks, benefits, limitations
of mammography, and
consider the patient’s
values/preferences.
Annual screening offers
the opportunity for
updating BC risk
assessments, modifiable
risk reduction
counseling, review of
red-flag symptoms, and
option for clinical breast
exams.

1-2: age >55
(Qualified
Recommendation)
NCCN4

40

1
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USPSTF5

40-49
(Grade C:
Selectively
Recommend)
50
(Grade B:
Recommend)

2
(Grade B:
Recommend)

9

74
(Grade B:
Recommend)

Grade C implies women
can choose the option to
initiate screening between
ages 40-49 years if they
value the potential benefits
of BCS mammography
greater than the potential
risks.

Adapted from:
1. American College of Obstetrics and Gynecologists (ACOG)
The American College of Obstetricians and Gynecologists. (2017). ACOG practice bulletin: Clinical management
guidelines for obstetrician-gynecologists Retrieved from https://www.acog.org/Clinical-Guidance-andPublications/Practice-Bulletins/Committee-on-Practice-Bulletins-Gynecology/Breast-Cancer-Risk-Assessment-andScreening-in-Average-Risk-Women?IsMobileSet=false
2. American College of Radiology (ACR)
Lee, C. H., Dershaw, D. D., Kopans, D., Evans, P., Monsees, B., Monticciolo, D., … Burhenne, L. W. (2010).
Breast cancer screening with imaging: Recommendations from the society of breast imaging and the ACR on the use
of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast
cancer. Journal of the American College of Radiology, 7(1), 18-27. doi:10.1016/j.jacr.2009.09.022
Monticciolo, D. L., Newell, M. S., Hendrick, R. E., Helvie, M. A., Moy, L., Monsees, B., . . . Sickles, E. A. (2017).
Breast cancer screening for average-risk women: Recommendations from the ACR commission on breast
imaging. Journal of the American College of Radiology, 14(9), 1137-1143. doi:10.1016/j.jacr.2017.06.001
3. American Cancer Society (ACS)
Oeffinger, K. C., Fontham, E. T. H., Etzioni, R., Herzig, A., Michaelson, J. S., Shih, Y. T., . . . Wender, R. (2015).
Breast cancer screening for women at average risk: 2015 guideline update from the American cancer
society. Jama, 314(15), 1599-1614. doi:10.1001/jama.2015.12783
4. National Comprehensive Cancer Network (NCCN)
Bevers, T. B., Helvie, M., Bonaccio, E., Calhoun, K. E., Daly, M. B., Farrar, W. B., . . . Kumar, R. (2018). Breast
cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology. Journal of the
National Comprehensive Cancer Network : JNCCN, 16(11), 1362-1389. doi:10.6004/jnccn.2018.0083
5. United States Preventive Services Task Force (USPSTF)
Siu, A. L. (2016). Screening for breast cancer: U.S. preventive services task force recommendation
statement. Annals of Internal Medicine, 164(4), 279. doi:10.7326/M15-2886

The United States Preventive Services Task Force (USPSTF) currently recommends
biennial mammograms for females starting at age 50 and continuing until age 74 (Siu, 2016). For
women ages 40 to 49, the USPSTF recommends selective screening based on individual factors,
given a lower net benefit of avoided breast cancer deaths versus harm (Nelson et al., 2016a; Sui,
2016). In this case, harm is defined as overdiagnosis and overtreatment. However, it is difficult
to quantify if evaluation and treatment of the diagnosed breast cancer found on imaging would
“become a threat to a woman’s health, or even apparent, during her lifetime” (Siu, 2016, p.280,
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para 2). The USPSTF proposes these guidelines based using a meta-analysis using absolute rates
that out of every 10,000 women aged 40-49 screened, there would be three fewer breast cancer
deaths, in comparison to eight fewer deaths for women aged 50-59, and 21 fewer deaths in
women aged 60-69 who had routine screening (Nelson et al., 2016a). This data implies younger
women completing routine mammograms experience less breast cancer related deaths than older
women, which would be expected since the incidence averages of breast cancer diagnosis and
death in the United States are ages 62 and 68 (SEER, n.d.). The USPSTF’s analysis of BCS
effectiveness regards breast cancer mortality reduction as the primary positive outcome across all
ages, as all-cause mortality was not found statistically significant, and the incidence of advanced
breast cancer diagnosis based on screening was only found reduced for women ages 50 or older,
but not for women ages 39-49 (Nelson et al., 2016a).
The USPSTF categorizes women who are considered average risk as those without
personal or familial breast cancer history, without known BRCA1 or BRCA2 gene mutation, and
without a history of radiation therapy to the chest at a young age (Sui, 2016). The USPSTF
recognizes women with familial breast cancer history or possible genetic BRCA1 or BRCA 2
mutations at higher risk of developing breast cancer and may benefit from initiating screening
earlier than 50 years (Nelson et al., 2016a; Sui, 2016). The USPSTF has a “B” recommendation
for screening women for BRCA mutations and referral for genetic counseling should occur
starting at age 18 and re-assessed “periodically” (Moyer, 2014, p. 274, para 2). However, no
further recommendations addressing the frequency of BRCA mutation screening is offered.
Screening recommendations for potentially high-risk women include those with familial
members with “breast, ovarian, tubal, or peritoneal cancer,” in addition to a positive screening
result from one screening risk model (FHS-7, Manchester Scoring System, Ontario Family
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History Assessment, Pedigree Assessment Tool, Referral Screening Tool) (Moyer, 2014, p. 271,
para 4). Females with risk factors or whom may experience significant familial medical history
changes over time may miss opportunities of being identified for early detection screening
without concrete recommendations.
In contrast, the National Comprehensive Cancer Network (NCCN) and American College
of Radiology (ACR) recommend annual mammogram screening to start at age 40 with
discontinuation dependent upon limited life expectancy (from factors such as co-morbidities,
age) determined by provider discretion and if no further interventions (i.e. additional imaging,
biopsies, breast cancer treatment) were to be pursued regardless of mammogram imaging results
(Bevers et al., 2018; Lee et al., 2010; Monticciolo et al., 2017).
American College of Obstetrics and Gynecologists (ACOG) (2017) advises women
should be counseled on BCS and be offered the choice to start mammograms at age 40 (but no
later than age 50) determined through a shared-decision between the patient and provider.
American Cancer Society (ACS) recommends annual screening mammogram starting at age 45
until age 54 (with individually tailored screening between the ages of 40-44), then every one to
two years starting at age 55 onwards, until life expectancy is less than 10 years (Oeffinger et al.,
2015).
The NCCN and ACR advocate for annual screening starting at age 40 because this age
group has the largest potential to experience the benefits of breast cancer mortality reduction,
improved survival rates, and better breast cancer treatment options (Bevers et al., 2018; Lee et
al., 2010). Per the ACS (2017a), estimated breast cancer death rates for women ages 40-49 were
9%, 19% for women ages 50-59, 23% for women ages 60-69, 20% for women ages 70-79, and
the highest occurrence of 27% in women aged 80 and above. The ACS’s recommendation to
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start mammograms at age 45 is based on quality evidence ratings found in their conducted
systematic review evaluating the harms and benefits of BCS in 5-year intervals (Oeffinger et al.,
2015). ACS advocates for introducing the discussion for BCS at age 40 to identify women at
higher risk that would benefit from mammography earlier than age 45 (Oeffinger et al., 2015).
ACOG (2017) endorses counseling for BCS starting at age 40, with the option to start
mammography because evidence from the ACS and USPSTF reviews found women receiving
mammograms between ages 40-49 experience quantifiable breast cancer mortality reduction
(Nelson et al., 2016a; Oeffinger et al., 2015). ACOG (2017) also supports a patient’s decision to
defer beginning mammograms until age 50, because determining an appropriate balance between
harm versus benefit is subjective and should incorporate the patient’s priorities and beliefs.
Overall these guidelines propose patient involvement through a shared decision making
approach, suggesting that BCS may not fit a standardized “one size fits all” approach.
There is general consensus amongst ACOG, ACR, ACS, and NCCN that women with
average risk of developing breast cancer are those without personal or familial breast/ovarian
cancer history, genetic predisposition for suspected or known gene mutations, or have a history
of ionizing radiation exposure to the chest at a young age (10-30 years) (ACOG, 2017; ACS,
2017a; Bevers et al., 2018; Daly et al., 2017; Lee et al., 2010). Depending on the risk factor,
women may benefit from earlier screening mammograms, additional imaging modalities, and
genetic counseling. Identifying and following women who may not have initial risk factors, but
develop them over time should be a part of a routine assessment, and re-evaluated regularly for
best management of comprehensive BCS practices. Other breast cancer risk factors identified
among these organizations include dense breast tissue, history of DCIS or LCIS, benign breast
disorders, women of Ashkenazi Jewish decent, nulliparity or first pregnancy after age 35, early
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menarche (age 11 or younger), late menopause (after 55 years), never having breastfed, postmenopausal combination hormone therapy, and post-menopausal high bone mineral density
(ACOG, 2017; ACS, 2017a; Lee et al., 2010). Environmental and behavioral influences
contributing to breast cancer include alcohol consumption, tobacco smoking, obesity,
diethylstilbestrol exposure, and working night shifts (ACOG, 2017; ACS, 2017a).
The lack of uniform BCS guidelines or a standardized decision toolkit for when to
implement screening has caused inconsistent practices in primary care, potentially affecting
outcomes for all women, including those at average or high risk. This difference in clinical
practice ultimately impacts the opportunity to optimally screen and re-screen women for breast
cancer in early detection, secondary, or tertiary care.
Current Practice and Insurance Coverage
Initiatives C-17 and C-18.1 from Healthy People 2020 aims for a 10% improvement in
the proportion of women ages 50-74 who receive BCS (target of 81.1%), and are counseled by
their providers about mammograms (target of 76.8%) (Office of Disease Prevention and Health
Promotion, 2018a). Data from the 2015 National Health Interview Survey indicates that only
71.6% of females aged 50-74 years in the United States receive BCS, and only 66.7% are
counseled by their providers about screening mammograms (Office of Disease Prevention and
Health Promotion, 2018a). The suboptimal screening rate shows a large percentage of the female
population was not offered screening for early detection, which can be a life-saving preventative
service. Conflict in recommendations among the ACOG, ACR, ACS, NCCN, and the USPSTF
regarding screening women under the age of 50, suggests there is a greater gap of missed
opportunities for providers to offer high-quality, comprehensive care to their patients.
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Radhakrishnan et al. (2017) conducted a national survey of primary care providers about
their BCS practices, and found that physicians primarily trusted BCS recommendations from
ACS, ACOG, and USPSTF. Each of these guidelines endorses different initial screening ages,
ongoing screening frequency, and age at which to discontinue mammography. In this study, 81%
of physicians reported offering BCS mammography to women aged 40-44, 88% to women aged
45-49, and 67% offered mammography to women 75 or older (Radhakrishnan et al., 2017).
These varying practices among providers represent the lack of a clear algorithm or screening
process that incorporates all the best evidence-based recommendations to provide high quality
care for optimal breast health. Furthermore, rescreening guideline practices fluctuate from
annually to biennially between organizations and for the ACS, the frequency changes from one
to two years after age 55. Radiology reports of the testing agencies performing the mammograms
often follow the ACR guidelines, which offers recommendation for annual screening for women
of all ages. In some cases, patients may be elicited back for routine annual follow-up by the
testing agency, which may directly conflict with the chosen practice guidelines of the primary
care institution. This implicates a potential for further confusion among primary care clinics
selecting a standard institutional recommendation to follow, as well as lack of clarity for
providers in navigating appropriate care for each female patient.
The current BCS practice that is most widely used, is the USPSTF guideline. The Centers
for Medicare and Medicaid Services (CMS) utilize the recommendations to establish the
standard protocol and evaluate core measures of quality health outcomes (Kaiser Family
Foundation, 2018). To date, Medicare Part B completely covers annual mammography screening
starting at 40, however, Medicaid BCS coverage is dependent on the Affordable Care Act (ACA)
criteria for that state (Kaiser Family Foundation, 2018). Many private and individual insurance
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plans fall under the ACA provisions that utilize the USPSTF’s grade “A or B” and Health
Resources and Services Administration (HRSA) practice recommendations (Kaiser Family
Foundation, 2018). The USPSTF grade “C” recommendation (stance originally published in
2009 and again in 2016) to selectively offer certain women to undergo mammography ages 4049, reflected in 2009 that not all health insurances were required to provide full insurance
coverage consequently creating a barrier of accessibility to screen for women in this age range
(Sui, 2016). In attempt to reduce this health disparity, in 2012 the Department of Health and
Human Services (DHHS) implemented a provision requiring the ACA to use the 2002 USPSTF
recommendations for BCS that entail a women can receive mammography starting at age 40
every one to two years with or without clinical breast exams (National Women’s Law Center,
2013). This provision remains enacted due to the passing of the Comprehensive Omnibus
Funding law in 2015 (Sui, 2016). HRSA (2018) also updated its recommendation guidelines in
2016 founded upon the Women’s Preventive Services Initiative (organized by ACOG) and
follow the same ACOG proposals. BCS is a preventative health service that should be offered to
any women seeking this care. Lack of insurance coverage or potential costs associated should not
interfere with universal preventative screens or prohibit a women’s access to BCS services.
Epidemiology. Worldwide, breast cancer is the most common cancer in females for both
the developed and underdeveloped countries (World Health Organization [WHO], 2018). With
estimates of 508,000 deaths due to breast cancer in 2011, 50% of cases and 42% of those deaths
occurred in developed countries. In the North and South Americas, there is a 25.2% incidence of
breast cancer in women of all ages and a 15.1% occurrence of death related to breast cancer
(Global Cancer Observatory, 2018). By 2030, it is projected in the North and South Americas
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there will be an additional 572,000 new breast cancer cases and 130,000 deaths with the United
States leading in breast cancer incidence (Global Cancer Observatory, 2018).
In 2015, the United States Cancer Statistics Working Group (2018) reported there were a
total of 242,476 females diagnosed with breast cancer. Of those diagnosed (Table 2), Caucasian
women experience the highest incidence of new breast cancer diagnosis, secondary to African
Americans, followed by Asians, Hispanics, and Native American women. While this data
captures the diagnosed rates, it is unclear whether the lack of screening contributes to these lower
rates among the minority population. This data also captures the age-specific rates of new breast
cancer diagnosis from 40-79 years (Table 3). This information reflects a clear escalation in the
quantity of women diagnosed with breast cancer as one ages. It is noteworthy that women aged
75-79 experience the second highest rate of new breast cancer diagnosis, but it is an ‘I’
(insufficient) recommendation by the USPSTF due to the lack of high-level evidence (United
States Preventative Services Task Force, 2019).
Table 2: 2018 Reported Number of females diagnosed with Breast Cancer
Number of Females
Diagnosed with
Breast Cancer per
100,000
White
125.6
Black
123.3
Asian/Pacific Islander
94.3
Hispanic
93.6
American Indian/Alaskan Native
71.2
United States Cancer Statistics Working Group. (2018). United States cancer statistics: Data
visualizations. Retrieved from https://gis.cdc.gov/Cancer/USCS/DataViz.html
Identified Race

Table 3: 2018 Reported Age Specific Rates of New Breast Cancer Diagnosis
Age

Number of Females
with New Breast
Cancer Diagnosis
per 100,000
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40-44
126.2
45-49
190.1
50-54
224.8
55-59
262.6
60-64
334.4
65-69
421.2
70-74
461.9
75-79
445.5
United States Cancer Statistics Working Group. (2018). United States cancer statistics: Data
visualizations. Retrieved from https://gis.cdc.gov/Cancer/USCS/DataViz.html
California’s leading cancer diagnosis is female breast cancer (NBCCEDP, 2013). At age
45-65, there is a 1:21 ratio for the probability of female breast cancer diagnosis in California, and
1:14 chance between ages 65-85 (American Cancer Society, 2013). Surveillance mammograms
have been identified as an effective screening tool for identifying breast cancer and when done
before an individual becomes symptomatic, early stage diagnosis and successful treatment with
cure is higher. If breast cancer is found to be localized at the time of diagnosis, the five-year
survival rate is 100% (American Cancer Society, 2013).
Setting
The Federally Qualified Health Center (FQHC) chosen for this doctoral project provides
care to women that are American Indians, Alaskan Natives, Black, Asian, Hispanics, and NonHispanics of the surrounding Bay Area (Oakland, Alameda, Richmond, and San Francisco). The
FQHC in Oakland primarily works with members that lack healthcare coverage, are underserved,
and have low socioeconomic status. Disparity factors of educational level, income, occupation,
and environmental exposures predispose and contribute to the risk of development of illness,
disease, and breast cancer (Office of Disease Prevention and Health Promotion, 2018a). The
opportunity to improve BCS coverage for all female members and possibly impact health
outcomes compelled the author to collaborate and conduct the project at this clinical site.
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From September 2017 to 2018, the race of women at FQHC aged 50-74 years that were
eligible for BCS (836 total) were identified (Table 4) as African American women as the highest
secondary to Latino or Hispanic women, followed by American Indian/Alaskan Native,
Caucasian, Asian, declined to specify/other/unknown, Native American, Native Hawaiian or
Pacific Islander, and Middle Eastern or North African. Of this population, compliance rates in
alignment with FQHC’s current standards that utilizes the UPSPSTF’s guidelines show Native
Hawaiian or Other Pacific Islander women with the highest mammogram completions and Asian
women with the lowest. Of the nine patient identified races, only Native Hawaiian or Other
Pacific Islander women currently meet Healthy People 2020’s C-17 objective target of an 81.1%
rate of receiving BCS (Office of Disease Prevention and Health Promotion, 2018a). The varying
rates of mammogram screening completions reflects an under performance in secondary
preventative care despite FQHC’s current system of screening. This reveals an opportunity for
improvement and understanding of how certain races have higher rates of mammography
completion and the barriers preventing those with lower percentages.
Table 4: Mammogram Screening Rates Based on FQHC’s Current Breast Cancer Screening
Guidelines (USPSTF: Biennial Screening for females ages 50-75)
Patient Identified Race

Eligible
(Total: 836)

Did Not Receive
Mammogram (Total: 237)

Compliance
Rate

Native Hawaiian or Other Pacific
Islander

30

3

90%

Latino or Hispanic

213

46

78.4%

Declined to
specify/Other/Unknown

39

9

76.9%

Native American-Multi-Race

38

10

73.6%

Black or African American

271

75

72.3%

Middle Eastern or North African

18

6

66.6%
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White

80

29

63.7%

American Indian/Alaskan Native

85

32

62.3%

Asian

41

21

48.7%

I2I Tracking search conducted for 9/10/17-9/10/2018
In Alameda County, the 2014 reported annual percentage of female breast cancer cases
diagnosed at an early stage (localized or in situ) are 76.9% for Non-Hispanic White, 65.9% for
African American, 70.4% for Hispanic, and 75.9% for Asian/Pacific Islander females
respectively (ACS, 2017b). The actual rates in percent are not available for the following
populations: American Indian and Alaskan Native females. However, the Office of Disease
Prevention and Health Promotion (ODPHP) suggest that about 53.1% of American Indians and
Alaska Natives females are screened with mammograms (Office of Disease Prevention and
Health Promotion, 2018c). This is 21.4% lower than the highest group of African American
women receiving breast cancer mammography within the last two years (Office of Disease
Prevention and Health Promotion, 2018c). Lower screening rates among this population reflect a
higher risk for missed routine care and preventative health services. With less access to
comprehensive care, these vulnerable populations will consequently suffer larger health
disparities.
Available Knowledge
Given all the various guidelines, there remains confusion among providers, about which
guideline is best and when to actually start screening. There is considerable debate about the
risks of mammography screening causing ‘harm’ to women in their 40s that could lead to
increased false-positives requiring additional imaging, the risk of radiation induced breast cancer
from the cumulation of mammography, the potential for overdiagnosis, and additional
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psychological stress (Nelson et al., 2016b). The PICOT questions asked to further understand the
current evidence, gaps, and risks of age-based routine breast screening are as follows:
1) Do guidelines (C) for starting BCS (O) in females (P) vary by age (T) for routine
screening mammograms (I)?
2) Do the contrasting (C) screening guidelines (I) affect outcomes for breast cancer
identification (O) in females (P) aged 40-49 (T)?
3) What are the advantages (O) and disadvantages (C) of starting screening early versus late
(I), for women aged 40-49 (P)?
4) What are the risk factors (I) predisposing women (P) towards developing breast cancer
(O) earlier than the general population (C)?
A systematic literature search was conducted in October 2018 and again in March 2019
to effectively evaluate available evidence. The databases searched were CINAHL, Cochrane
Database of Systematic Reviews, and PubMed. Keywords and MESH terms included
mammography, age factors, adverse effects, benefits, risk factors, BRCA1/2 mutations, family
history, chest radiation outcomes, breast neoplasms, breast cancer, and screening alone and in
combinations. Gray area literature and search engines utilized were ACOG, ACR, ACS, CDC,
NCCN, UpToDate, and USPSTF. Reference lists of preliminary research articles were scanned
for articles that could be considered for further review. Inclusion criteria were: articles published
between 2008-2019 for the most current data and existing practices recommended to the public
and health care providers regarding BCS, and articles written only in the English language. A
total of 136 articles were found, 21 were selected for further consideration based on the inclusion
criteria, and 8 were included in this review. Articles excluded did not further clarify and answer
the reviews aim in evaluating best practice management of BCS for women aged 40-49. Multiple
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studies that were reviewed included meta-analysis’, systematic reviews,
prospective/retrospective studies, and practice guideline recommendations. The evidence was
evaluated using the John Hopkins Research and Non-Research Evidence Appraisal Tools (2012a,
2012b) and rated for quality (Appendix C). The articles presented in this paper range from Level
I A to III C.
Review of Literature
After thorough examination of the current evidence, the leading arguments of the
potential risks and benefits of BCS practices are described to help educate the author and readers
to make informed, comprehensive decisions about breast health. The themes of possible
disadvantages towards screening women ages 40-49 are false-positive recalls from
mammography, false-positive readings leading to biopsy, overdiagnosis of breast cancer leading
to potential unnecessary treatment, psychological stress, and mammography related radiation
risk. Beneficial themes of screening women ages 40-49 reviewed are earlier stage of breast
cancer diagnosis, decreased breast cancer related mortality, increased number of lives saved from
routine BCS, and the potential of years of life gained from earlier detection (Appendix C).
Disadvantages to Breast Cancer Screening with Mammography (for women aged 40-49)
False-Positives. The potential risk for women receiving a false-positive finding from a
mammogram that is truly negative for breast cancer has been documented as a considerable
factor that can influence the individual decisions towards BCS. Pace and Keating (2014), the
USPSTF, and the ACS systematic reviews demonstrate a 61.3% (95% CI) risk of receiving at
least one false-positive finding over 10-years for women who started annual screening at age 40,
and 41.6% (95% CI) respectively for those continuing with biennial screening (Nelson et al.,
2016b; Oeffinger et al., 2015). However, comparable estimates for false positives in women
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starting mammogram screening in their 50s were discovered at 61.3% (95% CI) annually and
42% biennially (Nelson et al., 2016b; Oeffinger et al., 2015; Pace & Keating; 2014). This
evidence shows women in their 40s will experience near identical estimates of false-positive
recalls compared to those in their 50s regardless of the screening interval. The Van den Ende et
al. (2017) systematic review examined the effects of BCS for only women aged 40-49 and found
a 20.5% cumulative risk of experiencing a false-positive finding within the first seven
mammograms. This finding suggests there is possibly lower rates of false-positives findings
indicating some variability for women aged 40-49 than reported by the USPSTF, ACS, and Pace
and Keating (2014) systematic reviews. The decision to choose whether this disadvantage
outweighs to begin mammogram screening during age 40 or 50 should be the choice of the
individual undergoing the intervention rather than the standardized guidelines produced by
governing institutions.
Myers et al. (2015) found false-positive mammograms leading to biopsy
recommendations for a first time screen increased with age (OR 1.40 aged 40-44, 1.75 for 50-54
years, and 1.75 for 55-59 years). Over the course of ten years, cumulative estimates of biopsy
recommendation from false-positive mammograms exhibit a 7% (95% CI) increased risk during
annual screening for women in their 40s versus a 9.4% risk for women in their 50’s (Myers et al.,
2015; Nelson et al., 2016b; Oeffinger et al., 2015). During biennial screening, the risk for false
positives for women in their 40’s was 4.8% versus 6.4% for women in their 50s (Myers et al.,
2015; Nelson et al., 2016b; Oeffinger et al., 2015). These results show that women in their 50’s
carry a higher risk for false positives than women in their 40’s regardless of annual or biennial
screening. This suggests the need to avoid the risk for false-positive findings with follow-up
recommendation for additional imaging or biopsy remains consistent at any age, and should not
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be a limiting factor with beginning screening at age 40 versus 50. Factors that could contribute
and affect false positive rates include breast density, type of imaging modality utilized,
postmenopausal hormone therapy, timing of first mammogram, interval rescreen rate, and lack of
comparison mammogram images (Nelson et al., 2016b; Oeffinger et al., 2015). Modifiable and
non-modifiable risk factors are not discussed with this study and could impact these results.
Overdiagnosis. Overdiagnosis might be considered the greatest harm for a woman
obtaining mammogram imaging. Overdiagnosis is defined as the diagnosis of “cancer with a
screening test (such as a mammogram or PSA test) that will never cause any symptoms. These
cancers may just stop growing or go away on their own” (National Cancer Institute, n.d.). The
ACS, USPSTF, Myers et al. (2015), Pace and Keating (2014), and van den Ende et al. (2017)
systematic reviews state overall predication estimates for breast cancer overdiagnosis range
widely from 0-54% due to varying measures such as the BCS practices utilized, disease
incidence with or without screening, inclusion or exclusion of ductal carcinoma in situ, and lead
time adjustments (described as the time gained before cancer incidence from early detection)
(Nelson et al., 2016b; Oeffinger et al., 2015). Furthermore, no one individual has the same
underlying predisposing risk factors, behavioral influences, values, socioeconomic status, and
access to resources. Due to the variability in estimating the impact of breast cancer overdiagnosis
from mammograms, Myers et al. (2015) and Oeffinger et al. (2015) determined the quality of
quantifiable data to be low. The ACS, USPSTF, Myers et al. (2015), Pace and Keating (2014),
and van de Ende et al. (2017) share the understanding that it is difficult to quantify the impact of
overdiagnosis because there lacks a clear consensus on the best approach of how to measure and
evaluate this outcome (Nelson et al., 2016b; Oeffinger et al., 2015). Without demonstrating
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sound quality evidence in the rates of overdiagnosis related to BCS, it is difficult to synthesize
this factor as an influence toward guideline recommendation and provider-to-patient counseling.
Psychological Impact. The USPSTF considers and accounts for the potential negative
psychological impact, that mammography screening may have on women, as a ‘harm’ to BCS
screening (Nelson et al., 2106b). USPSTF found that women who had negative mammogram
results experienced less anxiety and distress than those with other outcomes (Nelson et
al.,2016b). Mixed results were reported and not found significant among for women not
returning to their next scheduled mammogram after experiencing a previous false-positive result
(Nelson et al., 2016b). Pace and Keating (2014) suggest that women with false-positive findings
experienced higher levels of situational distress but did not elicit the diagnosis of major
depressive or anxiety disorder. Evaluating the extent of individualized concern caused by factors
from potential negative outcomes of screening is a subjective finding that is balanced differently
for each patient and difficult to translate across a general population.
Mammography Radiation Risk. There are currently no studies that directly measure the
risk of cumulative mammography radiation induced breast cancer (Nelson et al., 2016b; van den
Ende et al., 2017). Rather, the USPSTF reports modeling studies predicted women aged 40-59
years experienced 11 per 100,000 radiation induced breast cancer deaths and 2 per 100,000 for
women aged 50-59 (Nelson et al., 2016b). ACOG (2017) states 125 of 100,000 women receiving
annual mammography ages 40-74 were diagnosed with radiation induced breast cancer from
mammograms that resulted in 16 deaths, but 968 breast cancer deaths were averted by screening.
These estimates elude that the possibility of avoiding multiple breast cancer deaths by decreasing
radiation exposure, may outweigh the potential risks of mammography to screen for cancer and
save other lives.
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Advantages of Screening (for women aged 40-49)
Surveillance mammograms have been identified as an effective screening tool for
identifying breast cancer and when done before an individual becomes symptomatic, early stage
diagnosis and successful treatment with cure is higher. If breast cancer is found to be localized at
the time of diagnosis, the five-year survival rate is 98.8% (SEER, 2018). Screening findings with
advanced cancer stages, has a five-year survival rate of 27.4% (SEER, 2018).
Earlier Diagnosis Stage. Mammograms conducted in women aged 40-49 offer the
opportunity to begin provider-to-patient education sooner, diagnose breast cancer earlier, treat
more successfully, and reduce overall mortality (Shen et al., 2011). A 10-year retrospective study
comparing women aged 40-49 with mammography (145) and non-mammography (166) detected
breast cancer exhibited smaller average tumor diameter size (20.68 mm versus 30.38 mm;
p<0.0001), less sentinel lymph node involvement (p<0.0001), increased 5-year disease free rate
(94% versus 71%) and better overall survival estimates (97% versus 78%) (Shen et al. 2011).
This statistically significant data demonstrates that females in their 40s who are at average risk
for developing breast cancer and receive mammograms earlier than the USPSTF’s
recommendations have better outcomes for earlier diagnosis, less reoccurrence or metastatic
spread, and less mortality rates (Shen et al., 2011). Women ages 45-49 and 50-54 experience the
same burden of disease (about 15% of years of life lost per age bracket) (Oeffinger et al., 2015).
Even with this knowledge, current practice guidelines conflict and differ amongst each other
prohibiting a cohesive standardized decision making model.
Decreased Mortality. Reduced breast cancer mortality in women who begin screening
with mammography in their 40s is evident across the majority of studies (Magnus et al., 2011;
Myers et al., 2015; Nelson et al., 2016a; Oeffinger et al., 2015; Pace and Keating, 2014). Van
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den Ende et al. (2017) report in their systematic review of four articles reviewing two
randomized controlled trials (the Age trial and the Canadian National Breast Screening Study-I
(CNBSS-1)) that there was no statistically significant difference found in breast cancer mortality
for women screened ages 40-49 years. However, van den Ende et al. (2017) identifies limitations
in both studies where the quality of mammogram technology and radiology interpretation in the
CNBSS-1 trial were possibly sub-standard, and in the Age Trial, after the initial mammogram,
all subsequent screenings were completed as single view instead of the standard two view
screening mammogram. Van den Ende et al. (2017) demonstrates the only non-significant
finding concerning breast cancer mortality reduction with screening women routinely in their
40s.
Magnus et al. (2011) meta-analysis found a 17% mortality reduction for women who had
screening mammograms between ages 39-49. Myers et al. (2015) and Pace and Keating (2014)
systematic reviews found a 15% mortality reduction for women beginning screening less than 50
years. The ACS graded the outcome of reduced breast cancer mortality evidence in women
younger than 50 as high (Oeffinger et al., 2015). The 5-year absolute risk of women developing
breast cancer at 5-year intervals is: 0.6% during ages 40-44, 0.9% during ages 45-49, and 1.1%
during ages 50-54 (Oeffinger et al., 2015). Mortality reduction is clearly evident in women
receiving mammograms earlier than 50.
Lives Saved/Potential Years of Life Gained. It is undeniable that mammography is the
best available diagnostic imaging modality and gold standard for detecting breast cancer (World
Health Organization, 2018). Pace and Keating (2014) found in their systematic review that 5 out
of every 10,000 women aged 40-49 years, 10 out of every 10,000 women aged 50-59 years, 42
out of every 10,000 women aged 60-69 years will be saved from mammograms. The USPSTF
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found biennial mammography for women aged 40-74 gained 152 lifetime years and avoided
eight breast cancer deaths per 1,000 versus women aged 50-74 gained 122 total years of life and
avoided seven breast cancer deaths (Sui, 2016). The ACR estimates based on their recommended
screening strategy, women receiving annual screening ages 40-84 per 1,000, experienced 11.9
BC deaths prevented, and 189 years of life gained (Monticciolo et al., 2017). ACR estimates
using the USPSTF’s recommendation for biennial mammography from ages 50-74 that 6.95 BC
deaths are prevented, and 110 years of life are gained (Monticciolo et al., 2017). Evidence
suggests those screened earlier and more frequently have the potential to experience lengthier
lives and fewer deaths.
Rationale
Theoretical/Conceptual Frameworks. The theoretical framework that will guide this
project is Jean Watson’s Philosophy and Science of Caring that encompasses the concepts of
human being, health, environment, and nursing (Petiprin, 2016). Watson identifies the human
being as a unique individual that requires the time, patience, and respect to be understood and
valued. She defines health as the physical and mental levels of well-being with efforts towards
the absence of disease. The environment focuses on health care professionals and their exposure
to socio-cultural experiences that provides opportunity to interact, reflect, and grow. Cultivating
personal and professional self-awareness allows for the provider to be present, non-judgmental,
and engaging in a caring manner with the patient. Watson’s model is parallel to the nursing
process in creating and establishing a comprehensive care plan that is holistic in nature.
Watson’s framework is grounded in approaching all human interactions in a caring
inquiry to promote health while valuing patient autonomy (Petiprin, 2016). These fundamental
concepts are what will structure the approach towards communicating and understanding
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perceived patient perceptions and values. BCS addresses health as a collaborative process
between provider and patient, encouraging establishment of a comprehensive care plan, and
ultimately optimizing breast health outcomes for each individual patient, instead of categorizing
patients into groups, costing lives.
The Tannahill Model of Health Promotion is the formative theory that will represent this
project’s approach towards identifying and addressing breast health among women. This model
aims at health promotion by incorporating community-based education through dissemination of
best available evidence, protection through policy implementation, and prevention or early
detection of disease through modern medicine (Tannahfill, 2009). This model will demonstrate
health promotion of female breast health through analyzation of current literature, sharing this
information to the health care team at FQHC, and implementing an easy-to-use standard of
practice toolkit to open a pathway for discussing and offering secondary screening measures for
breast cancer.
The “appropriateness in patient care” is the conceptual framework that will be the
foundation in creating an algorithm for the Screening Mammogram Initiation Protocol (SMIP) at
FQHC. This will also help formulate the approach and process of how providers are to lead
consultation with their patients regarding breast health. Sharpe & Faden (1996) proposes
“appropriateness” is characterized by valuing three point of views of the clinician, the patient,
and the society. This framework emphasizes clinical recommendation by the health care provider
are to be based on counseling best available literature. Discussion of all the available options and
their potential outcomes with consideration of the patients’ values and preferences are integral
components of valuing “appropriateness” (Sharpe & Faden, 1996). This concept in patient care
highlights the significance of informed consent that is based on evidence, is non-biased, and a
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process of shared decision making between the patient and the provider. As critical as it is for a
clinician to disseminate information on recommended medical interventions while weighing the
health benefits versus risk for each patient, if the proposed intervention does not align with the
patient’s principles, then it is considered inappropriate to implement at that visit.
While treating the whole person in a holistic manner, it is essential to integrate scientific
knowledge to ensure optimal patient outcomes. Evidenced based practice theory is the
fundamental guide for the purpose of this Doctorate of Nursing Practice (DNP) project and
efforts toward a practice change at FQHC. This theory promotes the dissemination of high-level
research based on a hierarchal ladder into clinical practice. Translating evidence into the health
care delivery system improves medical care and is vital towards meeting public health needs
(Institute of Medicine, 2001). However, while evidence can be generalized in the efforts of a
high-level study, sometimes evidence based practice theory can be contradictory in practice as
the population is not generalized and may require more individualized approaches. Each patient
is an individual with different values that are uniquely influenced by their social, environmental,
spiritual, cultural beliefs, and experiences. This is a reminder that a harmonious balance between
medicinal science and patient intervention is a collaborative process which urges an informed
decision, requiring clinician dissemination of information and patient-centered decision making.
Specific Aims
By February 2019, primary care providers at the FQHC will receive an educational
module on BCS guidelines, understand the importance of the evidence behind the current
guidelines, and apprehend techniques for individualized approaches to screening mammograms
using the Screening Mammogram Initiation Protocol (SMIP), developed by the author as a tool
for aiding decision making for best screening initiation timeframe and cancer risk assessments
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(Appendix K). The providers will be able to participate in shared decision making, using an
evidence based standardized approach. Screening may start early for some women, compared to
the current approach of starting all women at age 50. Appropriate recommendation of care will
be coordinated by achieving each of these objectives with the SMIP:
● Evaluate current best evidence and create an algorithm for breast cancer mammogram
screening appropriate to risk and age for each female
● Assess and evaluate best approaches for successful implementation of algorithm
● Present educational session and implement SMIP into practice
● Improve provider knowledge and counseling/recommendation for mammogram with
female members
Section III: Methods
Context
The SMIP protocol will be implemented using an educational and integrative approach.
Education regarding BCS, discussion about guidelines, a review of current practice and risks,
along with implementation of this algorithm in the clinic work flow to achieve full
implementation of this protocol will be applied.
Stakeholders
Key stakeholders that will be directly involved with this project proposal include the
DNP student, DNP chair, site leader, general practitioners, clinic management, and clinic staff.
Recipients that will be affected by this intervention include female patients and their families of
FQHC, their insurances/government, diagnostic testing centers, and specialty oncology clinics.
Interventions
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After reviewing the current BCS guidelines and risk factors, the SMIP will be created by
the DNP student. The SMIP is an evidence-based strategy designed as an algorithm for
healthcare providers to educate and navigate women about their breast health throughout their
life trajectory. This screening provision is an opportunity for professional development among
healthcare professionals, a public outreach initiative to promote screening on disparate
populations, and improvement on quality and assurance of reproductive services provided
(National Breast and Cervical Cancer Early Detection Program [NBCCEDP], 2013). After
collaborating with the DNP chair and site leader for the SMIP approval, the DNP student will
meet with the FQHC director for project proposal and approval to implement the project.
Education of providers will occur during one of their monthly, morning provider training
meetings. A 10-minute PowerPoint presentation will be provided as an in-service to FQHC staff
with handouts of the SMIP. Pre-surveys from the providers will also be collected.
The SMIP will be initiated the following week for 9-weeks for data collection. Currently,
identified from I2I Tracking the medical assistants highlight female patients age 50-74 that are
due for their biennial mammogram and are listed for clinical visits the following day. During
their visit, either the medical assistant will ask if the patient needs a mammogram referral request
and if they have further questions a discussion with the provider can occur. With the SMIP,
identifying patients the day before will be eliminated. Instead, during the rooming process the
medical assistants will review with female members ages 40 and 45, their risk factors for breast
cancer (that can include the Gail Model assessment), then record and report findings to the
treating provider. From those responses, the provider will be able to guide the discussion about
the patient’s individualized breast cancer risks and help the patient make an informed decision
about mammography screening. From the providers documentation, the patient’s preference on
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the interval for mammograms will be viewable for future management in secondary screening
care. Post surveys will be collected by the DNP student completed by the providers at the end of
the project implementation. Analyzation of all data collected from pre/post surveys and I2I
Tracking will be completed by the DNP student with assistance from Dr. Sandhu.
By integrating the SMIP into FQHC’s practice, the project will offer overall greater
awareness towards screening services for all female members, an EHR system with I2I Tracking
that aligns and supports provider practice changes, a reduction in barriers and increased access to
BCS (NBCCEDP, 2013). Increased and appropriate BCS, re-screening, and surveillance will
impact health outcomes by reducing breast cancer morbidity and mortality, and reduce health
disparities.
Gap analysis
The current standards of practice for mammogram screening at the FQHC follow the
USPSTF guidelines. The USPSTF recommends biennial mammograms for women 50 and over
who are at average risk until age 74 (Siu, 2016). A Family Nurse Practitioner at the FQHC
initially shared concern over when to start the conversation with patient’s about BCS, when to
order mammography, and when to schedule follow-up imaging. He and other providers at the
FQHC shared despite the governing USPSTF guidelines that initiate mammogram screening at
age 50, there is no screening for any additional risks, or educating women about the possibility of
starting earlier or at more frequent intervals. Mammograms are then continued biennially as per
the recommendations of the USPSTF. Furthermore, considering females with breast cancer risk
factors, there is no standard at FQHC guiding provider practices among earlier initial screening
age, frequency, discontinuation, as well as mammogram test result recommendations for next
routine follow-up.
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The lead Nurse Practitioner for this project was interviewed for a detailed gap analysis
(Appendix D and E). The NP site leader expressed BCS and follow-up varies not only among
providers, but also among different organizations, citing that every unremarkable radiology
imaging report recommends to schedule the next mammogram in one year. This
recommendation directly conflicts with the USPSTF’s guidelines to image every 2-years for an
average risk patient. From his interactions, other providers have expressed similar opinions and a
general consensus of confusion with when to start, rescreen, and discontinue mammogram
practices with their female population.
At the FQHC, I2I Tracking is a repository system that extracts electronic health record
data from NextGen for the institution to understand areas of high performance and needs for
improvement to support quality health outcomes, efficiency, and financial responsibility.
Utilization of I2I Tracking found between the 12 months of September 2017-2018, 838 females
ages 50-74 (parameters determined based on the FQHC’s current standards of care adopted by
the USPSTF guidelines) were eligible for breast cancer mammograms. Out of those 838 females,
599 were referred by clinicians and received mammograms showing a near 72% compliance.
When age parameters were expanded from ages 40-74 (based on the ACOG, NCCN, and ACR’s
initial start age), 1322 females at the FQHC were eligible and 837 females were referred and
received mammograms reflecting a 63.7% rate of mammography screening. This data suggests
that provider practices are inconsistent with current FQHC standards for BCS mammography,
and/or risk factors are not cohesively identified to implicate initiating earlier mammogram
referral.
GANTT
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This DNP project will take place from October 2018-April 2019. A GANTT chart
illustrates the proposed project’s timeline (Appendix F). Each task is reflected with which month
each of these milestones are planned to be completed. These tasks follow the nursing process by
first identifying the needs of FQHC’s clinic through assessing the work environment and then
determining a project idea. Planning will occur through a literature review and creating a practice
based screening tool (SMIP). Implementation is conducted with an educational presentation with
subsequent utilization in clinical practice for nine-weeks. This will simultaneously follow an
evaluation with data collection and analysis. Lastly, the DNP student will complete the project
summary and write-up to further disseminate the overall findings.
Work Breakdown Structure
The primary responsibility of the development, planning, implementation, and evaluation
of this project is the DNP student (Appendix G). The DNP student will facilitate, coordinate, and
lead this project with the support of the DNP chair, Dr. Sandhu and the clinical site mentor. The
DNP student will work with Dr. Sandhu to develop the Screening Mammogram Initiation
Protocol (SMIP). The DNP student will provide an educational PowerPoint in-service, and help
implement the SMIP. The Site Leader will extract the data collected on I2I Tracking for analysis.
Health Care Providers and Medical Assistants will utilize the SMIP into clinical practice over a
nine-week period. The DNP student will be able to utilize information collected from I2I
Tracking and surveys to evaluate the projects efficacy and success.
SWOT Analysis
An analysis of the strengths, weaknesses, threats, and opportunities to the project have
been performed to identify foreseeable issues with proposed solutions to support the success of
this project (Appendix H).
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Strengths. The FQHC’s health care providers have expressed a need to better address
and counsel patients on BCS and referral for mammograms. Integrating a standardized process
will help maintain accountability to aid in prompting providers when their patients are due for
mammogram screening discussion. Easy access of the algorithm with printed laminated handouts
will help appropriately guide the screening process to improve identification of women eligible
for mammography and are to receive counseling. This project has the opportunity to increase
provider knowledge, enhance patient involvement, and provide both patient and provider
empowerment in making decisions. Subsequently, this will foster collaborative discussions with
members to promote patient centered care. Ultimately this can increase patient satisfaction scores
and improve continuity of screening services, early detection, and referral for treatment in
primary care.
Weaknesses. Potential issues that exist and challenge this project’s success include a lack
of a currently existing algorithm, differing views and/or limited time from providers, a lack of
opportunity within the timeframe of the intervention, and possible lack of participation from the
patients, given the time constraints and needs for enhanced education. A change in any protocol
can be confusing for patients and take time to adopt. Development of an algorithm that has never
been tested requires dedication and time to research and formulate. Utilization in a confined
period can hinder the potential of a larger sample size for analysis. Health care providers may not
prioritize BCS discussion in comparison to other acute health issues. Providers may also not
have sufficient time between visits to optimally discuss breast health due to the lack of resources.
Beliefs and values of the patient based on culture and/or religion can affect patient opinions of
obtaining mammograms. Modern medicinal practices can be considered an invasive intervention
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in comparison to complementary alternatives such as the connectedness of spiritual healing and
consciousness of balance between all elements that is practiced in Native American culture.
Opportunities. A culture shift is occurring towards emphasis on preventative health and
screening in primary care. Many opportunities exist to improve the quality of care at FQHC.
Including BCS discussions as part of the routine well women annual exam will raise awareness
and promote holistic care. The Centers for Medicare and Medicaid created an electronic clinical
quality measure, CMS125v6 to monitor the 2018 performance of women ages 50-74 obtaining
mammograms to screen for breast cancer (Electronic Clinical Quality Improvement Resource
Center, 2018). Starting screening early in some females and ensuring that screening will happen
by age 50 for all females, will help the FQHC meet the goals of quality healthcare. The use of a
standardized protocol will create a flow for early conversation and hopefully mitigate further
delays in achieve successful screening mammogram rates. Production of this measure highlights
the importance of monitoring screening rates in primary clinical care. The United States
Department of Health and Human Services Health Resources and Services Administration (n.d.)
further developed a detailed overview of the BCS quality measure to emphasize the importance
of addressing high quality assurance in healthcare to improve outcomes.
Effective screening will improve Healthy People’s 2020 target goals towards reducing
health disparity rates of cancer related “illness, disability, and death” (Office of Disease
Prevention and Health Promotion, 2018a). The National Committee for Quality Assurance
(2018) Healthcare Effectiveness Data and Information Set shows the 2017 BCS rates based off
of insurance coverage within the last two years among women ages 50-74 were 72.7% for
commercial Health Maintenance Organization (HMO) insurance, 70.2% commercial Preferred
Provider Organization (PPO) coverage, 58.3% HMO Medicaid, 72.5% HMO Medicare, and
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72.2% PPO Medicare. This clinical performance shows up to a 13.9% range in variability of
screening rates, suggesting the type of care coverage an individual has contributes towards the
quality of comprehensive health sought and delivered. In 2016, “only 22% of uninsured women
aged 40-64 received a mammogram in the past year, compared to 54% of insured women”
(American Cancer Society Cancer Action Network, 2016, para. 2). Furthermore, females not
getting screening included 30% not insured, 62% uninsured, 25% college graduates, and 47%
with less than 12 years of education further potentiating socioeconomic disparities (American
Cancer Society Cancer Action Network, 2016).
Threats. Foreseeable threats that challenge the success of this project are the varying
institutional and government agency guidelines on BCS, cultural/language barriers, and
misinterpretations or errors of the algorithm. Adapting reputable guidelines onto one document
will reflect the best attempt at integrating, while respecting all current screening
recommendations but will not have proven generalizability. However, this will promote patientcentered care and decision making that will be established with the provider.
Budget
This project will not require significant financial cost, rather a commitment of time from
the stakeholders and those directly affected by the intervention (Appendix I). Cost of supplies for
the educational presentation is projected to be about $110 and the student developing,
implementing, and evaluating this project will not be financially compensated. The presentation
will be conducted during the FQHC’s monthly required provider in-service training meetings.
Implementation of the SMIP will occur during a patient’s well-women annual visit and will be of
no extra cost. Due to the Affordable Care Act, women are no longer discriminated by health
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insurance coverage and have access to preventative care without cost-sharing (National
Women’s Law Center, 2013).
The economic burden of cancer in the United States in 2010 were estimated to be $124.5
billion, $16.5 billion towards female breast cancer as the highest cancer cost (Yabroff et al.,
2011). In the United States an average cost of a mammogram for an uninsured individual is
$102, with Oakland, CA $130 respectively (Cost Helper, 2018b and New Choice Health, 2019).
However, all new health insurance companies after the Affordable Care Act was initiated in
2012 are required to cover mammograms every one to two years for women over 40 years
without cost-sharing or co-payments (National Women’s Law Center, 2013). Breast cancer
treatment varies by stage and can involve surgery (i.e. lumpectomy or mastectomy),
chemotherapy and/or biotherapy, radiation, and other ancillary treatments for symptom
management, adverse or side effects, and unanticipated hospitalizations.
Insured patients receiving breast cancer treatment can easily reach their yearly out-ofpocket maximum from labs, copays for prescription drugs, physician visits, and individual drugs
or treatments not covered by their insurance plan (Cost Helper, 2018a). For patients without
insurance, surgery costs range from $15,000-$50,000, chemotherapy $10,000-$100,000 (or
$7,000-$40,000 per treatment), with a total costs of treatment averaging $100,000 to $300,000
for advanced cases (Cost Helper, 2018a). For an average risk women ages 45-65, there is a 1:21
chance for developing breast cancer (ACS, 2013). For every 21 mammograms for uninsured
females it will cost $2142, less than any single treatment modality for diagnosed breast cancer
that typically is comprised as multi-regimen.
Communication Matrix
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Integrating each organization’s recommendation into an easily comprehensible and
usable toolkit will require current evidence-based research and planning (Appendix J). Project
research, development, coordinating, and facilitation of this project will be the primary
responsibility of the DNP student. Continual communication with the DNP chair and site leader
will be conducted as appropriate to the project needs via in-person, email, and phone.
Outcome Measures
Based on current best evidence, the DNP student with guidance from the DNP chair, will
create the SMIP intervention to standardize mammogram screening and referral in primary care.
This intervention will help reduce missed screening opportunities due to a standardized protocol
that integrates current evidence with EHR prompt reminders. This proposed intervention will
improve health care provider knowledge and confidence to educate and offer appropriate
referral. Outcome measures for this project’s intervention will reflect the following:
● At least 80% of providers will increase their knowledge of when and how to counsel
female members about breast health.
● At least 25 patients will receive counseling/recommendation for mammogram using the
SMIP starting at age 40.
● At least 50% of the providers will acknowledge satisfaction with utilizing the SMIP
algorithm for BCS.
Analysis
Qualitative data will be collected through pre and post educational and implementation
surveys completed by health care providers at the FQHC. This data will reflect on the quality of
the education provided, the feasibility using the SMIP algorithm, and open feedback from
providers implementing the intervention. Quantitative data will be comprised of general and
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anonymous information collected from the electronic I2I Tracking. Data for analysis will include
the number of females starting BCS at age 40 and 50, and the number of females eligible and
referred for a mammogram. Quantitative information from the electronic I2I Tracking will be
extracted into Excel spreadsheet software for analysis and evaluation. Planned data analysis will
include the change in percent of knowledge, the change in percent of patients referred for
mammogram, and the percentage rates of satisfaction using the Likert scale.
Ethical Considerations
This project focuses on quality improvement using evidence-based change in clinical
practice (Appendix A). This project examines BCS practices before and after the project’s
intervention to female members at the FQHC that are primarily high-risk and have less access to
resources. Competing reputable organizations recommend differing BCS practices that are
notably earlier than the FQHC’s current standards of practice that follow the USPSTF
Guidelines. Health promotion is an on-going and applicable beneficent goal for every patient.
Health care providers are responsible for educating patients and caregivers by providing
comprehensive information to facilitate their right to make decisions (American Nurses
Association, 2015). Health care providers are also responsible for utilizing evidence-based
medicine in practice where appropriate. Determining appropriateness of screening should not be
the sole responsibility of the provider, when guidelines that vary exist. Despite cultural/religious
preferences, language barriers, or personal biases, it is a provider’s “authority, accountability,
and responsibility [to] take action consistent with the obligation to promote health and provide
optimal care” (American Nurses Association, p. 7, 2015). Counseling on all opportunities to
screen should be based on the values of patient benefits versus harm and is a collaborate and
autonomous discussion between patient and provider. This project is a non-research project
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which will evaluate a quality improvement method, and does not require IRB approval
(Appendix A).
Section IV: Results
Results
A total of 25 staff members (nurses, behavioral health, social work, advanced practice
providers, physicians, and CEO) participated in the BCS educational presentation. Eleven
providers participated in the pre/post knowledge surveys and nine completed the nine-week postimplementation evaluation (Appendix N). I2I Tracking recorded the number of eligible female
participants for BCS and the number referred by providers based on the age ranges of 40-49 and
50-59 between February 6th- April 10th, 2019 (Appendix O).
Pre/Post Knowledge Surveys. The pre knowledge survey was administered prior to the
start of the educational, in-person presentation with the post knowledge survey provided after
presentation completion (Appendix L). Questions one and two asked providers how well they
understood the current BCS protocol at the FQHC of average and high-risk female patients with
available options as ‘less than I would like’, ‘about right’, and ‘more than I would like’
(Appendix N). Results reflected a 19% and 36.5% improvement after the post-educational
session. Question three evaluated how versed providers felt in regard to other various screening
guidelines (ACOG, ACR, ACS, NCCN, USTPSTF) with selections to answer from ‘not at all
well informed,’ ‘somewhat well informed,’ and ‘very well informed.’ The post knowledge
survey showed a 26.5% increase where providers felt they were ‘very well informed.’ Question
four supported a near unanimous response that providers felt it was ‘very important’ that patients
receive counsel about mammogram screening guidelines to make individualized screening goals
based on risk assessment. Only one response in the post knowledge survey chose it was
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‘somewhat’ important to provide shared-decision making BCS. Ninety percent answered
(previously 82%) that at this time they were ‘very likely’ to implement an individualized
screening protocol based on risk factors. One answered in the post knowledge survey they would
‘somewhat likely’ utilize the SMIP. Free response feedback of “great work, I feel well informed
after your lecture” and “thanks ☺” were written in the post-education.
Post Implementation Survey. The post implementation survey was provided by the
clinical site mentor at the subsequent FQHC staff meeting on April 10th, 2019 (Appendix L).
Eighty-nine percent felt ‘very comfortable’ using the SMIP after nine-weeks and 11% felt
‘somewhat comfortable’ (Appendix N). In question two, 89% answered that it was ‘very
feasible’ to incorporate the project into a women’s annual exam and 11% ‘somewhat feasible.’
Fifty-five percent of providers responded ‘yes,’ that they were more engaged in making BCS
decisions with their patients using the SMIP, 33% ‘somewhat,’ and 11% ‘not at all.’ As a
provider, 89% replied ‘yes’ that they saw value in initiating the SMIP protocol, 11%
‘somewhat,’ and 0% ‘not at all.’ Open feedback responses were “Not sure if I’m really using this
protocol, I use the USPSTF recommendations,” “I love laminated patient education tools!,”
“great job! Go dons!,” and “great work! Great protocol.”
I2I Tracking Results. The electronic I2I Tracking system found after nine-weeks from
the start of implementation that out of 842 women aged 40-49 that were eligible for BCS, 609
received referrals from their providers (Table 5 & Appendix O). Seventy two percent were
screened during the implementation phase in comparison to 64% pre-project. For women aged
50-59, 555 were eligible for BCS, 445 were referred from their providers, and 80% were
screened (previously 73%).
Table 5:
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Percent Screened Pre Project
9/10/17-9/10/18
40-49
64%
50-59
73%
(I2I Tracking search)
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Percent Screened Post Project Implementation
2/6/19-4/10/19
72%
80%

Section V: Discussion
Summary
Although there were minimal unfavorable responses in the pre/post knowledge and postimplementation surveys, overall feedback was positive and exceeded all desired project
outcomes. Providers responded that they better understood the various BCS guidelines and the
FQHC’s BCS protocol for not only average risk, but also high-risk female patients. Providers
weighed near unanimous importance in counseling women about their breast health and choosing
when to start mammography based on individual risk factors. Nearly 90% of providers
acknowledged satisfaction using the SMIP and during the nine-week implementation, 609 female
patients ages 40-49 received provider referral for mammography.
Interpretation
For women under age 50, an 8% increase in the number of women who were referred for
mammograms was observed. Based on these I2I Tracking results, however only an assumption
can be made that the SMIP protocol was followed, since no direct patient or provider data was
analyzed. For women aged 50-59, a 7% increase in mammogram recommendation referrals were
completed by providers, improving FQHC’s BCS practice protocol, Health People 2020’s
initiatives C17 and 18.1, and meeting all various screening recommendations (regardless if it is
the latest start age for their respective guidelines). It can be inferred that this project’s
educational session and non-validated SMIP tool improved provider knowledge and
understanding of BCS and supported comprehensive counseling for women to make informed
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decisions about their breast health. It can be inferred that toolkits identifying women at risk for
breast cancer or place higher value in the benefits of mammography over the ‘harms,’ are
necessary in primary care to support the opportunity for earlier screening and potential diagnosis.
It can be concluded that at this time there is no clear consensus on BCS recommendations, but
rather it should be the choice of the patient after non-biased counsel by their respective provider.
Instead of examining the number of completed mammograms, reimbursement measures should
rather measure the number of women who received counseling on BCS.
Limitations
Unavoidable limitations without breaking HIPAA and requiring the assistance from the
informational technologist to build tracking features in the EHR were if patients completed their
mammogram after a referral was made, and if patients who received comprehensive BCS
counsel by their respective provider chose not to have a mammogram at that time. Future studies
examining the barriers for women to complete their screening mammogram and factors weighing
the decision for or declining to start mammography are suggested to better improve the SMIP
and overall BCS. A confounding variable that could have influenced the outcomes of this project
was the need for the clinic to meet the 2018 Healthcare Effectiveness Data and Information Set
(HEDIS) measures. HEDIS tracks and supports funding for FQHC with one measure directly
examining BCS rates for women aged 50-74 years. The drive for the clinic to meet these
requirements could have indirectly contributed to the increased rates of referral for women ages
50-59, but overall is supportive of improved breast health outcomes.
Conclusions
In light of advancing technology and the shift towards precision health, primary
healthcare providers have the opportunity to initiate the discussion and counsel women on the
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risks, benefits, and limitations of BCS while incorporating patient values and preferences. There
is an opportunity to promote BCS in various populations and decrease health disparities using
primary care practice tools such as the SMIP. National goals to increase BCS interventions can
be met and positively influence quality health care outcomes, screening efficiency, delivery of
care, financial performance, and patient-provider satisfaction. Shared-decision making between
provider and patient coupled with standard breast screening guidelines can ultimately empower
women about breast health and improve patient outcomes.
Section VI: Other Information
Funding
This doctoral project received no sources of funding from any organization in the design,
implementation, interpretation, and reporting of this work.
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Appendix A: DNP Statement of Non-Research Determination

DNP Statement of Non-Research Determination Form
Student Name:___Lacrisha Go_______________________
Title of Project: Standardizing Mammogram Screening in Primary Care: Integrating an
Evidence Based Approach
Brief Description of Project: Mammogram screening practices for breast cancer vary
between initial start age, frequency, and discontinuation among reputable organizations.
Both modifiable and non-modifiable risk factors has caused even further confusion in the
screening process. This has consequently resulted in inconsistent provider practices
within primary care and ultimately impacted early identification of breast cancer and its
mortality. The purpose of this project is to create and implement a breast cancer
screening algorithm for providers in primary care to identify, assess, collaborate, and
refer women for mammogram testing using the appropriate guidelines and risk factor
assessments based on age.
A) Aim Statement: By March 2018, primary care providers at the Federally Qualified
Health Center (FQHC) will utilize a standardized approach for routine screening
mammograms using the Screening Mammogram Initiation Protocol (SMIP).
B) Description of Intervention: The DNP student will create the SMIP and lead an
educational training session to FQHC health care providers and medical assistants
about the breast cancer mammogram screening algorithm. Participants will utilize the
information taught in the presentation to effectively implement and utilize the toolkit
into practice. Six weeks after initial project implementation, the DNP student will
connect with project manager to collect statistical information from I2I tracking and
evaluate intervention’s effectiveness from completed staff surveys.
C) How will this intervention change practice? This intervention will reduce missed
opportunities of initial screening by standardizing the breast cancer screening process
for all female patients at FQHC. It will help increase health care provider knowledge
and empowerment to counsel and encourage collaboration of comprehensive plans
with their patient.
D) Outcome measurements: 1) At least 80% of providers will increase their
knowledge of when and how to counsel female members about breast health. 2) At
least 25 patients will receive counseling/recommendation for mammogram using the
SMIP starting at age 40. 3) At least 50% of the providers will acknowledge satisfaction
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with utilizing the SMIP algorithm for breast cancer screening.

To qualify as an Evidence-based Change in Practice Project, rather than a Research Project, the
criteria outlined in federal guidelines will be used:
(http://answers.hhs.gov/ohrp/categories/1569)

X This project meets the guidelines for an Evidence-based Change in Practice Project as
outlined in the Project Checklist (attached). Student may proceed with implementation.

☐This project involves research with human subjects and must be submitted for IRB approval
before project activity can commence.
Comments:
EVIDENCE-BASED CHANGE OF PRACTICE PROJECT CHECKLIST *

Instructions: Answer YES or NO to each of the following statements:
Project Title:
The aim of the project is to improve the process or delivery of care with
established/ accepted standards, or to implement evidence-based change. There is
no intention of using the data for research purposes.
The specific aim is to improve performance on a specific service or program and is
a part of usual care. ALL participants will receive standard of care.
The project is NOT designed to follow a research design, e.g., hypothesis testing
or group comparison, randomization, control groups, prospective comparison
groups, cross-sectional, case control). The project does NOT follow a protocol that
overrides clinical decision-making.
The project involves implementation of established and tested quality standards
and/or systematic monitoring, assessment or evaluation of the organization to
ensure that existing quality standards are being met. The project does NOT
develop paradigms or untested methods or new untested standards.
The project involves implementation of care practices and interventions that are
consensus-based or evidence-based. The project does NOT seek to test an
intervention that is beyond current science and experience.
The project is conducted by staff where the project will take place and involves
staff who are working at an agency that has an agreement with USF SONHP.
The project has NO funding from federal agencies or research-focused
organizations and is not receiving funding for implementation research.
The agency or clinical practice unit agrees that this is a project that will be
implemented to improve the process or delivery of care, i.e., not a personal
research project that is dependent upon the voluntary participation of colleagues,
students and/ or patients.
If there is an intent to, or possibility of publishing your work, you and supervising
faculty and the agency oversight committee are comfortable with the following

YES
X

X
X

X

X

X
X
X

X

NO
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statement in your methods section: “This project was undertaken as an Evidencebased change of practice project at X hospital or agency and as such was not
formally supervised by the Institutional Review Board.”

ANSWER KEY: If the answer to ALL of these items is yes, the project can be considered an
Evidence-based activity that does NOT meet the definition of research. IRB review is not
required. Keep a copy of this checklist in your files. If the answer to ANY of these questions
is NO, you must submit for IRB approval.
*Adapted with permission of Elizabeth L. Hohmann, MD, Director and Chair, Partners Human
Research Committee, Partners Health System, Boston, MA.

STUDENT NAME (Please print):
________Lacrisha J. Go___________
__________________________________
Signature of Student:
______________________________________________________DATE____________

SUPERVISING FACULTY MEMBER (CHAIR) NAME (Please print):
________________________________________________________________________
Signature of Supervising Faculty Member (Chair):
______________________________________________________DATE____________
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Appendix C: Evaluation Table
Citation

Design/Method/
Measure

Magnus
et al.,
2011

A meta-analysis
evaluating BCS
mortality for women
aged 39-49. Sources
reviewed (August
2009-December 2009)
using the Cochrane,
Educational Resources
Information Center,
Medline, Ovid, and
PubMed databases.
Quality of evidence
evaluated by two,
independent
reviewers.

Myers et
al., 2015

Sample
Variables
&
Studied and
Setting Their Definitions
Nine
IV: Age
randomi
zed
DV: Breast
controlle cancer diagnosis
d trials
and mortality
included

Systematic review of
Ten
available evidence on randomi
the harms and benefits
zed
of breast cancer
controlle
screening. Sources
d trials,
reviewed (September
72
2013 and March 2014) observat
using CINAHL,
ional
PyschINFO, and
studies,
PubMed databases.
one

IV: Age,
mammography,
clinical breast
examinations
DV: Breast
cancer mortality,
overdiagnosis,
life expectancy,

Data
Analysis

Findings

Appraisal: Worth to
Practice

DerSimonia
n and Laird
random
effects
model using
the STATA
statistical
software
version
10.1.

Breast cancer
mortality reduction
found with women
aged 39-49 receiving
routine
mammography.

Implications: Evidence
suggests that women
younger than 50 yearsold experience a
reduced incidence of
breast cancer mortality
with mammogram
screening.

Summary
estimates,
qualitative
synthesis

Limitations: All
studies evaluated were
conducted >10 years
ago reflecting possible
outdated imaging
modality and treatment
options.
“Moderate” quality of
evidence that
mammography
screening is correlated
with mortality
reduction for women
ages 40-69 and an
increase in falsepositive results with
recommendation for

LOE: I
Implications: Based on
variability and the
quality of available
evidence it is difficult
to determine which
breast cancer
screening
recommendation
should be followed.
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Quality of evidence
evaluated using the
Grading of
Recommendations
Assessment,
Development, and
Evaluation framework.

Nelson
et al.,
2016a

Update on the 2009
USPSTF systematic
review with metaanalysis on the
effectiveness of BCS.
Sources analyzed
(June, 2015) using
MEDLINE and
Cochrane databases.

modelin
g study,
and
seven
reviews

Thirtyeight
articles
included
(Eight
randomi
zed
controlle
d trials)

quality-adjusted
life expectancy

IV: Age, imaging
modalities
utilized
DV: Breast
cancer mortality,
stage of diagnosis
outcomes, and
all-cause
mortality
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biopsy over 10 years
in the United States.
“Low” evaluation of
evidence found
between the best
intervals of screening,
overdiagnosis, qualityadjusted life
expectancy, and
association with
clinical breast
examinations and
mortality.
Random
Increased breast
effects
cancer mortality
modeling, reduction found as one
profileaged with routine
likelihood
mammogram
modeling,
screening in
Cochran
randomized control
chi-square
trials, however
tests, I2
different indications
statistic,
indicated with two
short and
observational studies.
long case
All cause-mortality
accrual
was not found to be
methods,
significant among any
absolute rate age. Advanced breast
reduction,
cancer reduction
Poisson
indicated to reduce for
modeling,
women ages 50 and
and Stata/IC
over.

Limitations: No
publication date limit,
level of evidence,
varying screening
methods,
advancements in
treatment technology
since studies
conducted
LOE: III

Implications: Further
research is necessary
to help guide
screening practices
Limitations: No
publication date limit,
advancements in
treatment and imaging
technology since
studies conducted
LOE: I
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version 13.1
(StataCorp)

Nelson
et al.,
2016b

Update on the 2009
FiftyUSPSTF systematic
nine
review on the harms of studies
BCS. Sources
included
analyzed (December
2014) using
MEDLINE and
Cochrane databases.

IV: Age
DV: Falsepositives,
overdiagnosis,
radiation
exposure, pain,
anxiety

Qualitative
synthesis

False-positive rates
Implications: Women
observed similarly for with more breast dense
women in the 40 and
tissue and are receive
50 ages, but overall
mammography
higher with women
annually are more
ages 40-49 especially likely to receive falsewith dense breast
positive results leading
tissue. Varying range to additional imaging.
of overdiagnosis found
Overdiagnosis is
among all modeling
difficult to determine
studies. Women with
because there is no
false-positive findings
standard of
found with more
measurement.
anxiety than women
Psychological impact
with negative
is a subjective finding,
mammography results. and the effects on each
Pain associated with
women differs.
mammography varied.
No studies found a
Limitations: Differing
direct association with
screening practices,
radiation induced
patient populations,
breast cancer from
modeling parameters
mammography
(i.e. DCIS diagnosis,
screening.
BC incidence)
LOE: III
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Oeffinge
r, et al.,
2015

Systematic review of
current BCS literature
conducted by the
Duke University
Evidence Synthesis
Group. Quality of
evidence evaluated
using the Grading of
Recommendations
Assessment,
Development, and
Evaluation framework
by the ACS’s
guideline development
group.

Not
clearly
delineat
ed

IV: Age of
diagnosis
DV: Breast
cancer mortality,
life expectancy,
false positives,
overdiagnosis,
quality of life,
tumor burden

58
Qualitative
synthesis

High quality strength
for breast cancer
mortality reduction in
women receiving
mammography
screening younger
than 50 years. False
positives found higher
with screening
annually than
biennially. The quality
of evidence estimating
overdiagnosis, life
expectancy with
screening, and qualityadjusted life
expectancy was
considered low.

Implications:
Grading of outcomes
vary between studies
and weigh harms
versus benefits
differently.
Recommendations by
ACS are a guidance,
but shared-decision
making is vital
between the provider
and the patient.
Limitations: Many
factors of each
individual study
affecting outcomes
(i.e. comparison of
age-groups, imaging
modality utilized, type
of screening, patient
population risk
factors), and outcomes
of evidence were
evaluated differently
to determine
recommendation (i.e.
modeling estimates,
empirical
comparisons)
LOE: III
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Pace &
Keating,
2014

Shen et
al., 2011

Systematic review of
harms and benefits of
BCS. Sources
analyzed using
Medline database and
manual search of
reference lists and
current practice
recommendations.
Quality of evidence
evaluated using the
American Heart
Association
guidelines.

Five
metaanalyses
included
to
evaluate
BCS and
mortalit
y
reductio
n,

A 10-year
1,581
retrospective chart
females
review through the
treated
Cancer Registry
for BC,
Database at an
311 ages
unidentified institution
40-49
for women ages 40-49
treated for BC that
followed the
Commission on
Cancer Programs
Standards.

IV: Age,
individual risk
factors of high
risk patients
DV: Breast
cancer mortality,
harms of
mammography
screening (falsepositives and
recommendation
for biopsy,
overdiagnosis),
and how to
support patients
in making
informed
decisions about
their breast health
IV: Age, annual
mammography
detected cancer,
nonmammography
detected cancer
DV: Breast
cancer diagnosis,
tumor
size/sentinel
lymph node
involvement at

59
Qualitative
synthesis

Descriptive,
statistical
analysis

Mammography found
to decrease BC
mortality and found
significant for women
in their 40 through 60
year ages. Evidence
shows there is a risk of
false-positives that is
higher the younger the
age. Overdiagnosis
estimates vary
between studies and
reports may be over or
underestimated.
Clinical decision
models can be used to
help best navigate best
clinical outcomes and
informed patient
decisions.
Women with
mammography
detected cancer were
found to have at
diagnosis smaller
tumor size, less
sentinel lymph node
involvement, higher
disease-free and better
overall survival rates
compared with women
with non-

Implications: Further
high, rigorous studies
needed to understand
true benefit/harm of
mammography. BCS
ought to be
individualized based
on risk factors and
patient priorities.
Limitations:
Publication date of
sources vary up to >10
years ago,
advancements in
treatment and imaging
technology since
studies conducted.
LOE: III
Implications: Multiple
benefits of annual
mammography for
women starting at age
40 exhibited.
Limitations: Study
conducted >10 years
ago
LOE: III

STANDARDIZING MAMMOGRAM SCREENING

Van den
Ende et
al., 2017

Systematic review of
Four
the harms and benefits articles
of BCS for women
examine
ages 40-49. Sources
d of two
analyzed (February
randomi
2017) using Embase,
ze
Medline, PubMed, and controlle
Cochrane databases.
d trials
Quality of evidence
evaluated using the
Grading of
Recommendations
Assessment,
Development, and
Evaluation framework.

diagnosis,
disease-free rate,
survival rate
IV: Age
DV: Breast
cancer mortality,
all-cause
mortality, falsepositives,
overdiagnosis
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mammography
detected cancer
Qualitative
synthesis

Breast cancer
reduction and allcause mortality not
found generalizable
and graded as
“moderate” quality of
evidence. False
positive recall
observed and
considered “high”
quality of evidence for
women ages 40-49.
Overdiagnosis based
on estimates.

Implications: More
rigorous randomized
controlled trails
needed
Limitations:
Randomization
contamination, prescreened participants,
study generalizability,
all studies conducted
outside the United
States (differing
screening practices of
invitation to screen
versus opportunity to
screen)

LOE: III
Key: LOE: level of evidence (Johns Hopkins Hospital/The Johns Hopkins University, 2012a, 2012b), IV: Independent variable, DV:
Dependent variable, BC: Breast cancer, BCS: Breast cancer screening
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Appendix D: Gap Analysis Interview with lead Nurse Practitioner
1. What are some existing standards of practice policies that you believe can be improved at
FQHC?
There is a lot of current evidence-based literature that can update and improve our health
care outcomes of our patients at the FQHC. The name of this clinic indicates a huge
opportunity to work with vulnerable populations where we can provide comprehensive,
thorough care to those with many health care needs. Improvements especially for funding of
our clinic include preventative health and secondary services such as screening for hepatitis,
HIV, TB, breast/cervical/colon cancer. Especially as DNP students, we have the access and
tools to make really positive change at a clinic like this.
2. What is the current process of identifying, managing, and follow-up for this practice and
existing health outcomes?
The current process of breast cancer screening is our Medical Assistants print out a sheet
of all our patients scheduled for the next clinic day. On this list, our I2I Tracking system
alerts which patient are in need of a preventative health or screening service. From this,
patients are notified by our panel manager that they are being referred for a mammogram.
Patients call the number on the referral and then obtain their mammogram at local outside
facilities. Reports are sent to their primary provider who then follow-up with the patient of
the results. Our standard of practice policy follows the USPSTF guidelines, but unremarkable
radiology imaging reports recommend to rescreen yearly. Our policy that is adopted from the
USPSTF recommends to screen every two years. It is also confusing when we should start
screening for patients with risk factors and why some women with no significant risk factors
are receiving mammograms younger than age 50.
3. Is there available data that can support for the opportunity in change in practice?
I2I Tracks is a great system used to extract our data from NextGen to help track and
indicate what preventative health measures are needed for each patient and reflects our
compliance rates at the clinic. Using I2I Tracks we are able to measure baseline data,
interventions that have been implemented at the clinic, and evaluate their effectiveness.
4. What are the desired outcomes for this practice change?
Outcomes of improving screening rates among all the providers would help maintain and
possibly increase our Community Health Center Network government funding for our lowincome clinic at FQHC. It would improve health outcomes for our patients and provider
satisfaction knowing we are providing the best available care current literature offers.
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Appendix E: Gap Analysis
Gap Analysis
Desired Situation
Optimize the breast cancer
mammogram screening
process to improve overall
breast health for women at
FQHC clinics.

Current Situation

Action Plan

FQHC follows the
USPSTF
recommendations on
breast cancer
mammogram
screening starting at
age 50 for all women,
however, evidence
suggests other options
available.

-Perform literature review on current
guidelines and best available
evidence
-Create Screening Mammogram
Initiation Protocol (SMIP)
-Present project proposal to DNP
chair for approval
-Present project proposal to Site
Leader for approval
-Provide PowerPoint presentation inservice to FQHC staff
-Implement SMIP for 6-weeks
-Collect, analyze, evaluate, and
disseminate findings
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Appendix F: GANTT Chart

Survey and
identify needs of
FQHC’s clinic for
potential project
Analyze current
recommendations
and complete
literature review
Create algorithm
Collaborate with
stakeholders to
introduce project
Provide
educational
training for
healthcare
providers and
medical assistants
Implement project
Collect data and
analyze
Disseminate
findings
Complete written
DNP project

Jul

Jun

May

Apr

Mar

Feb

2019

Jan

Dec

Nov

Oct

Sep

Jul

Task/Description

Aug

Project GANTT
2018
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Appendix H: SWOT Analysis
Strengths
● Health care professionals have
expressed a need to better identify,
address, and counsel on breast cancer
screening and referral for mammogram
at the FQHC
● Increase provider involvement,
knowledge, and empowerment
● Increase patient satisfaction scores in
receiving comprehensive health
coverage
● Provide early detection, diagnosis, and
breast cancer treatment
● Cost effective with ongoing
surveillance, prevention, and early
detection
Opportunities
● Increase quality of care and optimize
breast health outcomes with female
patients
● Meets Healthy People 2020 goals
towards reducing health disparities,
cancer related disability and mortality
● Standardize breast cancer policy and
procedure screening in primary care
● Decrease morbidity and mortality rates
especially among a high-risk population
● Raises awareness and promotes early
detection, diagnosis, and treatment

Weaknesses
● No toolkit currently exists that
incorporates current evidence of best
practices on breast cancer mammogram
screening from reputable institutions
and government agency
● Resistance from medical assistants
and/or health care providers that there is
too little time or not as high of a priority
to implement during visit
● Lack of opportunity to use breast cancer
mammogram algorithm within time
frame of project
● The FQHC already follows the
USPSTF’s grade “A” and “B”
guidelines for breast cancer screening
Threats
● Competing institutions and government
agency’s recommend varying guidelines
on initial screening, frequency, and
discontinuation of mammograms
● Cultural/language barriers
● Misunderstandings of algorithm
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Appendix I: Budget
Description

Calculations

Total Cost

Project Manager time

($67.70/hour x 135 hours = $9,140.60)1

$0
(DNP student Project)

Provider time

($75.48/hour x 3 hours x 6 providers =
$1,358.69)3

$1,358.69

Medical Assistant time

($23.25/hour x 3 hours x 6 medical
assistants = $418.50)4

$418.50

Printed Material
(handouts and toolkit)

$70

$70

Food for in-service

$40

$40

Space Rental

$0

$0

Equipment

$0

$0

(Includes time for
presentation, pre/post
surveys, and utilizing
toolkit)

Total Budget

$1,887.19

1. Glassdoor. (2019a). Registered nurse salaries in San Francisco, California area. https://www.glassdoor.com/Salaries/sanfrancisco-registered-nurse-salary-SRCH_IL.0,13_IM759_KO14,30.htm
2. Glassdoor. (2019c). Family Nurse Practitioner salaries in San Francisco, California area. Retrieved from
https://www.glassdoor.com/Salaries/san-francisco-family-nurse-practitioner-salary-SRCH_IL.0,13_IM759_KO14,39.htm
3. Glassdoor. (2019d). Certified medical assistant salaries in San Francisco, California area. Retrieved from
https://www.glassdoor.com/Salaries/san-francisco-certified-medical-assistant-salary-SRCH_IL.0,13_IM759_KO14,41.htm

Burden of Breast Cancer Disease to the United States Healthcare System
2010 Cost Estimate for all Cancers

$124.5 billion

2010 Cost Estimate for Breast Cancer

$16.5 billion

2018 Projected New Breast Cancer Diagnosis

266,120 (30%- Leading)

2018 Projected Breast Cancer Deaths

40,920 (14% - Second highest)

2010-2014 Breast Cancer Incidence in California State

120.7 per 100,000
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Estimated Cost of Breast Health for an Uninsured Female Patient
Average cost of mammogram per patient

$102

Average total cost of breast cancer treatment per patient

$100,000

Estimated Lifetime Cost of Mammograms for an Uninsured Female Patient Based off of
Guidelines
USPSTF

$1,224

ACOG

$3,570

ACR (if discontinued at age 75)

$3,570

ACCS (if discontinued at age 75 annually)

$3,570

(if discontinued at age 75 and started biennially after 55)

$2,550

NCCN (if discontinued at 75)

$3,570
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Appendix J: Communication Matrix
Information

Audience

Time

Methods of Communication

Project planning and

DNP Chair

Weekly-

Email

coordination

Site Leader

Biweekly

In-person

DNP Student
Project modifications

DNP Chair

Phone
As needed

DNP Student

Email
In-person
Phone

Project issues and

DNP Chair

resolutions

DNP Student

As needed

Email
In-person
Phone

Milestone completions

DNP Chair

Monthly

Email

Site Leader

In-person

DNP Student

Phone
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Appendix K: Screening Mammogram Initiation Protocol (SMIP)

Initial Screen at age 40*2

*At anytime, if patient
has a first degree
relative with positive
breast cancer history
initiate mammograms
10 years from
diagnosis

-Per ACOG1 (but can delay first mammogram up to 50 years), ACR2 , & NCCN3
-ACS4 Individualized (Qualified recommendation)
-USPST F5 Individualized (Grade: C Selectively Recommend)

Review Non-Modifiable Risk Factors for Breast Cancer 6
-Personal or family (parent, sibling, and/or child) history of breast cancer
-Previous breast biopsy
-History of radiation therapy to the chest
-Known or suspected BRCA mutation
-Early onset of menses between ages 7-11
-Nulliparous or late parity (after age 35)
-Ashkenazi Jewish Decent
No
-Document decline with reason
-Document counseling/assessment

Ye s

Refer for
Mammography
Ye arly
-Per ACOG1
(option for
biennial too),
ACR2 , NCCN3 ,
and ACS4 if
starting

Rescreen at age 45
ACS4

-Per
(Strong recommendation)
-Review Non-M odifiable Risk Factors (listed above)

Biennial
Until age 50 if
patient desires

No
-Document decline with reason
-Document counseling/assessment

Yes

Re fe r for
Mammography

Rescreen at age 50
Yearly
-Per ACS4 until age 54, after
55 patient-provider
discussion until life
expectancy <10 years to do
every 1-2 years

Bie nnial
Until age
50 if
patient
desires

-Per USPST F5 (Grade: B
Recommend)
Patient
de sires
screening

No
-Document decline with reason
-Revisit topic yearly at wellwoman annual visit

Refer for
Mammography
Yearly
ACOG1 until 75, anything beyond patient-provider
discussion
-Per ACR2 until life expectancy <5-7 years or if no further
intervention planned regardless of imaging results
-Per NCCN3 until life expectancy limited and no further
intervention planned regardless of imaging results
-Per ACS4 until age 54, after 55 patient-provider
discussion until life expectancy <10 years
-Per

Biennial
-Per USPST F5 until age 74
-Per ACS4 starting at age
55 every 1-2 years until life
expectenacy <10 years
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Adapted from:
1. American College of Obstetrics and Gynecologists (ACOG)
The American College of Obstetricians and Gynecologists. (2017). ACOG practice bulletin:
Clinical management guidelines for obstetrician-gynecologists Retrieved from
https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Bulletins/Committee-onPractice-Bulletins-Gynecology/Breast-Cancer-Risk-Assessment-and-Screening-in-AverageRisk-Women?IsMobileSet=false
2. American College of Radiology (ACR)
Lee, C. H., Dershaw, D. D., Kopans, D., Evans, P., Monsees, B., Monticciolo, D., … Burhenne,
L. W. (2010). Breast cancer screening with imaging: Recommendations from the society of
breast imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and
other technologies for the detection of clinically occult breast cancer. Journal of the American
College of Radiology, 7(1), 18-27. doi:10.1016/j.jacr.2009.09.022
Monticciolo, D. L., Newell, M. S., Hendrick, R. E., Helvie, M. A., Moy, L., Monsees, B., . . .
Sickles, E. A. (2017). Breast cancer screening for average-risk women: Recommendations from
the ACR commission on breast imaging. Journal of the American College of Radiology, 14(9),
1137-1143. doi:10.1016/j.jacr.2017.06.001
3. National Comprehensive Cancer Network (NCCN)
Bevers, T. B., Helvie, M., Bonaccio, E., Calhoun, K. E., Daly, M. B., Farrar, W. B., . . . Kumar,
R. (2018). Breast cancer screening and diagnosis, version 3.2018, NCCN clinical practice
guidelines in oncology. Journal of the National Comprehensive Cancer Network :
JNCCN, 16(11), 1362-1389. doi:10.6004/jnccn.2018.0083
4. American Cancer Society (ACS)
Oeffinger, K. C., Fontham, E. T. H., Etzioni, R., Herzig, A., Michaelson, J. S., Shih, Y. T., . . .
Wender, R. (2015). Breast cancer screening for women at average risk: 2015 guideline update
from the American cancer society. Jama, 314(15), 1599-1614. doi:10.1001/jama.2015.12783
5. United States Preventive Services Task Force (USPSTF)
Siu, A. L. (2016). Screening for breast cancer: U.S. preventive services task force
recommendation statement. Annals of Internal Medicine, 164(4), 279. doi:10.7326/M15-2886
6. National Institute of Health: National Cancer Institute. (n.d.). The breast cancer risk
assessment tool. Retrieved from https://bcrisktool.cancer.gov

Created for educational purposes. Copyright © 2019 by Lacrisha Go and Prabjot Sandhu
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Breast Cancer Screening Guidelines
Group

Age to Initiate
Mammograms

Frequency (years)

Age to Discontinue
Mammograms

ACOG1

40*
No later than 50

1-2*

75, anything beyond is
provider-patient discussion

ACR2

40

1

Life expectancy <5-7 years
or if no further intervention
planned regardless of
imaging results

ACS3

40-44
(Qualified Recommendation)

1: ages 40-44 if starting
(Qualified Recommendation)

Life expectancy <10 years
(Qualified
Recommendation)

45
(Strong Recommendation)

1: ages 45-54
(Qualified Recommendation)
1-2: age >55 (Qualified
Recommendation)

NCCN4

40

1

Limited life expectancy
and no further intervention
planned regardless of
imaging results

USPSTF5

40-49
(Grade C: Selectively
Recommend)

2
(Grade B: Recommend)

74
(Grade B: Recommend)

50
(Grade B: Recommend)
Adapted from:
1. American College of Obstetrics and Gynecologists (ACOG)
The American College of Obstetricians and Gynecologists. (2017). ACOG practice bulletin: Clinical management
guidelines for obstetrician-gynecologists Retrieved from https://www.acog.org/Clinical-Guidance-andPublications/Practice-Bulletins/Committee-on-Practice-Bulletins-Gynecology/Breast-Cancer-Risk-Assessment-andScreening-in-Average-Risk-Women?IsMobileSet=false
2. American College of Radiology (ACR)
Lee, C. H., Dershaw, D. D., Kopans, D., Evans, P., Monsees, B., Monticciolo, D., … Burhenne, L. W. (2010 ).
Breast cancer screening with imaging: Recommendations from the society of breast imaging and the ACR on the use
of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast
cancer. Journal of the American College of Radiology, 7(1), 18-27. doi:10.1016/j.jacr.2009.09.022
Monticciolo, D. L., Newell, M. S., Hendrick, R. E., Helvie, M. A., Moy, L., Monsees, B., . . . Sickles, E. A. (2017).
Breast cancer screening for average-risk women: Recommendations from the ACR commission on breast
imaging. Journal of the American College of Radiology, 14(9), 1137-1143. doi:10.1016/j.jacr.2017.06.001
3. American Cancer Society (ACS)
Oeffinger, K. C., Fontham, E. T. H., Etzioni, R., Herzig, A., Michaelson, J. S., Sh ih, Y. T., . . . Wender, R. (2015).
Breast cancer screening for women at average risk: 2015 guideline update from the American cancer
society. Jama, 314(15), 1599-1614. doi:10.1001/jama.2015.12783
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4. National Comprehensive Cancer Network (NCCN)
Bevers, T. B., Helvie, M., Bonaccio, E., Calhoun, K. E., Daly, M. B., Farrar, W. B., . . . Kumar, R. (2018). Breast
cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology. Journal of the
National Comprehensive Cancer Network : JNCCN, 16(11), 1362-1389. doi:10.6004/jnccn.2018.0083
5. United States Preventive Services Task Force (USPSTF)
Siu, A. L. (2016). Screening for breast cancer: U.S. preventive services task force recommendation
statement. Annals of Internal Medicine, 164(4), 279. doi:10.7326/M15-2886
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Appendix L: Pre-and-Post Knowledge and Project Implementation Surveys

UNIVERSITY OF
SAN FRANCISCO
Breast Cancer Screening Pre Knowledge -Survey
1. How well do you understand current breast cancer screening protocol practiced at the
Federally Qualified Health Center for average risk female patient’s?
More than I would like

About right

Less than I would like

2. How well do you understand the current breast cancer screening protocol practiced at
the Federally Qualified Health Center for high risk female patient’s?
More than I would like

About right

Less than I would like

3. How well informed are you regarding the various guidelines for screening mammograms
(ACOG, ACR, ACS, NCCN, USPSTF)?
Very well informed

Somewhat well informed

Not at all well informed

4. How important is it to you to counsel patients about mammogram screening guidelines
to select individualized patient screening goals based on risk factors?
Very important

Somewhat important

Not at all important

5. How likely are you to implement an individualized screening protocol based on risk
factors at this time?
Very likely

6. Comments/Feedback:

Somewhat likely

Not at all likely
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UNIVERSITY OF
SAN FRANCISCO
Breast Cancer Screening Post Knowledge -Survey
1. How well do you understand current breast cancer screening protocol practiced at the
Federally Qualified Health Center for average risk female patient’s?
More than I would like

About right

Less than I would like

2. How well do you understand the current breast cancer screening protocol practiced at
the Federally Qualified Health Center for high risk female patient’s?
More than I would like

About right

Less than I would like

3. How well informed are you regarding the various guidelines for screening mammograms
(ACOG, ACR, ACS, NCCN, USPSTF)?
Very well informed

Somewhat well informed

Not at all well informed

4. How important is it to you to counsel patients about mammogram screening guidelines
to select individualized patient screening goals based on risk factors?
Very important

Somewhat important

Not at all important

5. How likely are you to implement an individualized screening protocol based on risk
factors at this time?
Very likely

6. Comments/Feedback:

Somewhat likely

Not at all likely
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UNIVERSITY OF
SAN FRANCISCO
Breast Cancer Screening Post Implementation Evaluation

1. How comfortable did you feel using the Screening Mammogram Initiation Protocol?
Very comfortable

Somewhat comfortable

Not at all comfortable

2. How feasible has it been to incorporate during a women’s annual exam?
Very feasible

Somewhat feasible

Not at all feasible

3. As a provider, using the SMIP tool, were you more engaged in making breast cancer
screening decisions with your patients?
Yes

Somewhat

Not at all

4. As a provider do you see the value in initiating the SMIP protocol?
Yes

5. Comments/Feedback?

Somewhat

Not at all
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Appendix N: Survey Results
Pre/Post Knowledge Data

Q1: How well do you understand current breast cancer screening
protocol practiced at the FQHC for average risk female patient’s?
1

Less than I would like

3

9

About right

8

1

More than I would like

0

1

2

3

4

Post

5

6

7

8

9

10

8

9

Pre

Q2: How well do you understand the current breast cancer
screening protocol practiced at the FQHC for high risk female
patient’s?
1

Less than I would like

5
8

About right

6
2

More than I would like
0

1

2

3

4

Post

Pre

5

6

7

STANDARDIZING MAMMOGRAM SCREENING

79

Q3: How well informed are you regarding the various guidelines
for screening mammograms (ACOG, ACR, ACS, NCCN, USPSTF)?
1

Not at all well informed

2

3

Somewhat well informed

6
7

Very well informed

3

0

1

2

3
Post

4

5

6

7

8

Pre

Q4: How important is it to you to counsel patients about
mammogram screening guidelines to select individualized patient
screening goals based on risk factors?
Not at all important

Somwhat important

1

2

Very important

9

0

2

4

6
Post

Pre

8

10

10

12
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Q5: How likely are you to implement an individualized screening
protocol based on risk factors at this time?
Not at all likely

1

Somewhat likely

2
10

Very likely

9

0

2

4

6
Post

8

Pre

Feedback Post-Education
"Great work, I feel well informed after your lecture"
"Thanks :)"
Post Implementation Data

Q1: How comfortable did you feel using the
Screening Mammogram Initiation Protocol?
9
8
7

6
5
4

3
2
1

0
Very comfortable

Somewhat comfortable

Not at all comfortable

10

12
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Q2: How feasible has it been to incorporate
during a women’s annual exam?
9

8
7
6

5
4
3

2
1
0

Very feasible

Somewhat feasible

Not at all feasible

Q3: As a provider, using the SMIP tool, were you
more engaged in making breast cancer screening
decisions with your patients?
6
5
4

3
2
1
0
Yes

Somewhat

Not at all
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Q4: As a provider do you see the value in
initiating the SMIP protocol?
9

8
7
6

5
4
3

2
1
0

Yes

Somewhat

Not at all

Feedback Post-Implementation
"I love laminated patient education tools!"
"Great job! Go dons!"
"Not sure if I'm really using this protocol, I use the USPSTF recommendations."
"Great work! Great protocol."
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Appendix O: I2I Tracking Results
9/10/17-9/10/18
Age

Number referred by
provider
863
617

Percent Screened
(Referred/Eligible)
64%
73%

Project Implementation: 2/6/19-4/10/19 (9 weeks)
Age
Number of eligible
Number referred by
participants
provider
40-49
842
609
50-59
555
445

Percent Screened
(Referred/Eligible)
72%
80%

40-49
50-59

Number of eligible
participants
1334
841

Women Ages 40-49 Referred for Mammography
74%
72%

70%
68%
66%

64%
62%
60%
Pre-Project

Post-Implementation

Women Ages 50-59 Referred for Mammography
82%
80%
78%
76%

74%
72%
70%

68%
Pre-Project

Post-Implementation

